Photodynamic therapy for enhancing antitumour immunity

Pizova, Klara; Tománková, Kateřina; Daskova, A.; Binder, Svatopluk; Bajgar, Robert; Kolářová, Hana

doi:10.5507/bp.2012.056

Cited by 38 publications

(33 citation statements)

References 95 publications

(104 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This possibility comes from evidence that micro satellite instability defines the immune microenvironment in some colorectal cancers, 201 that the presence of a high mutation rate improves immunotherapy responses, 9 and that suicide-gene therapy and photodynamic therapy increase tumour immunogenicity. 202,203 HDAC and PARP inhibitors as well as other chemo therapeutic agents could potentially enhance radiation-induced tumour immunity by similar mechanisms.…”

Section: Local and Systemic Responsesmentioning

confidence: 97%

Opportunities and challenges of radiotherapy for treating cancer

2015

View full text Add to dashboard Cite

The past 20 years have seen dramatic changes in the delivery of radiation therapy, but the impact of radiobiology on the clinic has been far less substantial. A major consideration in the use of radiotherapy has been on how best to exploit differences between the tumour and host tissue characteristics, which in the past has been achieved empirically by radiation-dose fractionation. New advances are uncovering some of the mechanistic processes that underlie this success story. In this Review, we focus on how these processes might be targeted to improve the outcome of radiotherapy at the individual patient level. This approach would seem a more productive avenue of treatment than simply trying to increase the radiation dose delivered to the tumour.

show abstract

Section: Local and Systemic Responsesmentioning

confidence: 97%

Opportunities and challenges of radiotherapy for treating cancer

2015

View full text Add to dashboard Cite

show abstract

“…The ability of PDT to induce activation of the immune system and specific antitumor immunity is a well-known phenomenon, recently reviewed in Pizova et al [165]. Indeed, the ignition of anticancer immunity is as important as tumor cell death in designing an optimal cancer therapy [12, 40, 166].…”

Section: The Response Of Immune System To Photodynamic Treatmentmentioning

confidence: 99%

Immunogenic Cell Death: Can It Be Exploited in PhotoDynamic Therapy for Cancer?

Panzarini

Inguscio

Dini

2013

BioMed Research International

View full text Add to dashboard Cite

Immunogenic Cell Death (ICD) could represent the keystone in cancer management since tumor cell death induction is crucial as well as the control of cancer cells revival after neoplastic treatment. In this context, the immune system plays a fundamental role. The concept of Damage-Associated Molecular Patterns (DAMPs) has been proposed to explain the immunogenic potential of stressed or dying/dead cells. ICD relies on DAMPs released by or exposed on dying cells. Once released, DAMPs are sensed by immune cells, in particular Dendritic Cells (DCs), acting as activators of Antigen-Presenting Cells (APCs), that in turn stimulate both innate and adaptive immunity. On the other hand, by exposing DAMPs, dying cancer cells change their surface composition, recently indicated as vital for the stimulation of the host immune system and the control of residual ill cells. It is well established that PhotoDynamic Therapy (PDT) for cancer treatment ignites the immune system to elicit a specific antitumor immunity, probably linked to its ability in inducing exposure/release of certain DAMPs, as recently suggested. In the present paper, we discuss the DAMPs associated with PDT and their role in the crossroad between cancer cell death and immunogenicity in PDT.

show abstract

“…3 Progression to HCC is often attributed to the lack of pathognomonic symptoms and poor prognosis. 4, 5 The currently available clinical interventions require extensive prior immunosuppressive treatments often leading to undesirable physiological events. 4 Hence, recent advances in immunotherapy advocate measures to stimulate the immune system, especially the adaptive immune responses that could have a paramount role in tumor destruction/regression and, as such, could serve as promising selective therapeutic targets in cancer.…”

mentioning

confidence: 99%

Hypericin-photodynamic therapy leads to interleukin-6 secretion by HepG2 cells and their apoptosis via recruitment of BH3 interacting-domain death agonist and caspases

et al. 2013

View full text Add to dashboard Cite

Photodynamic therapy (PDT) has emerged as a capable therapeutic modality for the treatment of cancer. PDT is a targeted cancer therapy that reportedly leads to tumor cell apoptosis and/or necrosis by facilitating the secretion of certain pro-inflammatory cytokines and expression of multiple apoptotic mediators in the tumor microenvironment. In addition, PDT also triggers oxidative stress that directs tumor cell killing and activation of inflammatory responses. However, the cellular and molecular mechanisms underlying the role of PDT in facilitating tumor cell apoptosis remain ambiguous. Here, we investigated the ability of PDT in association with hypericin (HY) to induce tumor cell apoptosis by facilitating the induction of reactive oxygen species (ROS) and secretion of Th1/Th2/Th17 cytokines in human hepatocellular liver carcinoma cell line (HepG2) cells. To discover if any apoptotic mediators were implicated in the enhancement of cell death of HY-PDT-treated tumor cells, selected gene profiling in response to HY-PDT treatment was implemented. Experimental results showed that interleukin (IL)-6 was significantly increased in all HY-PDT-treated cells, especially in 1 μg/ml HY-PDT, resulting in cell death. In addition, quantitative real-time PCR analysis revealed that the expression of apoptotic genes, such as BH3-interacting-domain death agonist (BID), cytochrome complex (CYT-C) and caspases (CASP3, 6, 7, 8 and 9) was remarkably higher in HY-PDT-treated HepG2 cells than the untreated HepG2 cells, entailing that tumor destruction of immune-mediated cell death occurs only in PDT-treated tumor cells. Hence, we showed that HY-PDT treatment induces apoptosis in HepG2 cells by facilitating cytotoxic ROS, and potentially recruits IL-6 and apoptosis mediators, providing additional hints for the existence of alternative mechanisms of anti-tumor immunity in hepatocellular carcinoma, which contribute to long-term suppression of tumor growth following PDT.

show abstract

Photodynamic therapy for enhancing antitumour immunity

Cited by 38 publications

References 95 publications

Opportunities and challenges of radiotherapy for treating cancer

Opportunities and challenges of radiotherapy for treating cancer

Immunogenic Cell Death: Can It Be Exploited in PhotoDynamic Therapy for Cancer?

Hypericin-photodynamic therapy leads to interleukin-6 secretion by HepG2 cells and their apoptosis via recruitment of BH3 interacting-domain death agonist and caspases

Contact Info

Product

Resources

About